Classification of Alzheimer’s disease stages from magnetic resonance images using deep learning

View article
PeerJ Computer Science

Main article text

 

Introduction

  • Early mild cognitive impairment (EMCI): the affected person starts experiencing episodes of memory loss with words or the location of household items, nevertheless he can function independently and participate in social activities.

  • Mild cognitive impairment (MCI): the affected people are susceptible to forgetting recent occurrences, becoming disoriented in their homes, and having difficulties with communication. This is often the longest stage of AD, lasting up to 4 years.

  • Late mild cognitive impairment (LMCI): at this stage of the disease, patients may need help with daily tasks, facing increasing difficulty communicating and controlling their movements. Their memory and cognitive skills worsen, and changes in behavior and personality may occur.

  • Alzheimer’s disease (AD): as the disease progresses, the affected person requires increasing levels of attention and aid with daily tasks. This stage is characterized by growing unawareness of time and space, problems recognizing family and close friends, difficulty walking, and behavioral disturbances that may even lead to aggression.

Methods

Dataset

Deep learning architectures

Siamese 3D

Vision transformer

DenseNet

EfficientNet

Training procedure

Results

Discussion

Conclusions

Additional Information and Declarations

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

Alejandro Mora-Rubio conceived and designed the experiments, performed the experiments, analyzed the data, performed the computation work, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.

Mario Alejandro Bravo-Ortíz performed the experiments, analyzed the data, performed the computation work, prepared figures and/or tables, and approved the final draft.

Sebastián Quiñones Arredondo performed the experiments, analyzed the data, performed the computation work, prepared figures and/or tables, and approved the final draft.

Jose Manuel Saborit Torres analyzed the data, prepared figures and/or tables, data collection and preparation, and approved the final draft.

Gonzalo A. Ruz conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Reinel Tabares-Soto conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:

The data is available from ADNI (https://adni.loni.usc.edu) and OASIS (https://www.oasis-brains.org).

The search parameters for ADNI database are available at Zenodo: Alejandro Mora-Rubio. (2023). MoraRubio/alzheimer-stages-dl: First Release (v1.0). Zenodo. https://doi.org/10.5281/zenodo.7855386.

Funding

This work was supported by the Universidad Autonoma de Manizales as part of the project “Detección de COVID-19 en imágenes de rayos X usando redes neuronales convolucionales” with code 699-106, and also to the projects “CH-T1246: Oportunidades de Mercado para las Empresas de Tecnología—Compras Públicas de Algoritmos Responsables, Éticos y Transparentes”, ANID PIA/BASAL FB0002, and ANID/PIA/ANILLOS ACT210096. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

12 Citations 1,894 Views 154 Downloads